JP2020523307A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523307A5
JP2020523307A5 JP2019567306A JP2019567306A JP2020523307A5 JP 2020523307 A5 JP2020523307 A5 JP 2020523307A5 JP 2019567306 A JP2019567306 A JP 2019567306A JP 2019567306 A JP2019567306 A JP 2019567306A JP 2020523307 A5 JP2020523307 A5 JP 2020523307A5
Authority
JP
Japan
Prior art keywords
treatment
angiogenesis
intraocular pressure
vegf antagonist
nvg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523307A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/065464 external-priority patent/WO2018229034A1/en
Publication of JP2020523307A publication Critical patent/JP2020523307A/ja
Publication of JP2020523307A5 publication Critical patent/JP2020523307A5/ja
Pending legal-status Critical Current

Links

JP2019567306A 2017-06-14 2018-06-12 血管新生緑内障を治療するための非抗体ｖｅｇｆアンタゴニスト Pending JP2020523307A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17176072 2017-06-14
EP17176072.1 2017-06-14
PCT/EP2018/065464 WO2018229034A1 (en) 2017-06-14 2018-06-12 Non-antibody vegf antagonists for the treatment of neovascular glaucoma

Publications (2)

Publication Number Publication Date
JP2020523307A JP2020523307A (ja) 2020-08-06
JP2020523307A5 true JP2020523307A5 (cg-RX-API-DMAC7.html) 2021-07-26

Family

ID=59070500

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019567306A Pending JP2020523307A (ja) 2017-06-14 2018-06-12 血管新生緑内障を治療するための非抗体ｖｅｇｆアンタゴニスト

Country Status (4)

Country Link
US (1) US20210138032A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020523307A (cg-RX-API-DMAC7.html)
TW (1) TW201904610A (cg-RX-API-DMAC7.html)
WO (1) WO2018229034A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
CN116585466A (zh) 2018-05-10 2023-08-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100514929B1 (ko) 1996-10-25 2005-09-15 길리애드 사이언시즈, 인코포레이티드 혈관내피 성장인자 핵산 리간드 복합체
ATE293640T1 (de) 1997-04-07 2005-05-15 Genentech Inc Anti-vegf antikörper
MXPA01012630A (es) 1999-06-08 2002-07-22 Regeneron Pharma Polipeptidos quimericos modificados con propiedades farmacocineticas mejoradas.
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
KR100897379B1 (ko) 2004-06-08 2009-05-14 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관신생-저해 키메릭 단백질 및 그 사용
MX359570B (es) 2008-11-03 2018-10-01 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
US20150297675A1 (en) 2012-08-28 2015-10-22 Aaron Osborne Use of a vegf antagonist in treating ocular vascular proliferative diseases

Similar Documents

Publication Publication Date Title
JP2020523307A5 (cg-RX-API-DMAC7.html)
Bignami et al. NK1 receptor antagonists as a new treatment for corneal neovascularization
Giannaccare et al. Anti-VEGF treatment in corneal diseases
Abdul-Kadir et al. Update on surgical management of complex macular holes: a review
JP2012072152A5 (cg-RX-API-DMAC7.html)
JP6931046B2 (ja) ｍＴＯＲ阻害剤を含有する黄斑変性治療用薬学組成物
JP5557408B1 (ja) 眼底疾患治療剤
EA032263B1 (ru) Применение ингибиторов ccr3
CA3025258C (en) Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
CN102105167A (zh) 轴性近视的预防或治疗剂
CN114845718B (zh) 用于治疗与过度血管形成相关的眼部疾病的化合物
WO2018022437A3 (en) Multikinase inhibitors and uses in ocular fibrosis
CN106604730B (zh) 角膜厚度调节剂
CN111683682A (zh) 用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物
Oliveira et al. VEGF TrapR1R2 suppresses experimental corneal angiogenesis
TW201904610A (zh) 用於治療新生血管型青光眼之非抗體vegf拮抗劑
Tanaka et al. Guanabenz and clonidine, α2-adrenergic receptor agonists, inhibit choroidal neovascularization
WO2013032853A1 (en) Activators of cxcr3 for the treatment of angiopathies of the eye
RU2575966C2 (ru) Способ лечения неоваскулярной глаукомы
CN110327350B (zh) 多巴胺d1受体拮抗剂sch39166在作为制备治疗眼部病理性血管新生药物的应用
US20080070855A1 (en) Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes
KR20180044237A (ko) 안압 하강 증강제
ES2628321T3 (es) Mejora del resultado de una trabeculectomía
RU2687592C1 (ru) Способ хирургического лечения макулярного отека, осложненного эпиретинальной мембраной, при сахарном диабете
Chanana et al. Premacular subhyaloid haemorrhage in Eales' disease managed with Nd: YAG laser